Breakthrough T1D was on site in New Orleans, LA from June 5-8 for the American Diabetes Association’s (ADA) 86th Scientific Sessions. Check out all of our coverage below, including type 1 diabetes (T1D) advances across all our mission priority areas and several Breakthrough T1D-funded researchers and staff driving progress forward.
In case you missed it, see below for a recording our Mid-Year Mission Update, featuring key takeaways from ADA and other exciting developments that we’re looking forward to in 2026.
ADA 2026: Days 1 and 2
ADA 2026: Days 3 and 4
Check out coverage from days 3 and 4 at ADA, including an update on Eledon’s tegoprubart.
Mid-Year Mission Update with Breakthrough T1D leadership
For more ADA news and 2026 T1D progress updates, tune in below to hear Breakthrough T1D Chief Executive Officer Aaron Kowalski, Ph.D. cover the top advancements presented at ADA 2026 alongside updates from our mission pillar leads, Sanjoy Dutta, Ph.D. (Chief Scientific Officer), Lynn Starr (Chief Global Advocacy Officer), and Thomas Danne, M.D., Ph.D. (Chief Medical Officer, International).
Thanks for joining us throughout our coverage of the ADA 86th Scientific Sessions. We were encouraged by continued progress across our mission priority areas, including cures therapies, treatments, and devices. Breakthrough T1D staff and leadership were on-site hosting and participating in panel discussions, meeting with industry leaders, and engaging with researchers from around the world to accelerate T1D mission progress. Breakthrough T1D-funded research was front-and-center, showcasing the reach of our impact driven by supporters like you. That’s a wrap on ADA 2026, and we’re already looking forward to ADA 2027!
